Randomised phase II trial of olaparib, chemotherapy, or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
<p><strong>Introduction:</strong> Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer have not...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
BMJ
2021
|